(AOF) – TME Pharma announces the success of the advisory meeting with the FDA on the development of NOX-A12 against brain cancer. Based on the information received, TME Pharma confirms that it is on track to prepare the submission of its applications for clinical trial authorization (Investigational New Drug – IND) and access to an accelerated regulatory pathway according to a schedule that will allow complete both by the end of the first quarter of 2024.
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
